Zymeworks (ZYME) Interest & Investment Income (2021 - 2026)
Zymeworks (ZYME) posted Interest & Investment Income of -$486000.0 for Q1 2026, down 1575.86% sequentially from -$29000.0 in Q4 2025, and down 189.01% YoY from $546000.0 in Q1 2025.
Analysis
Zymeworks (ZYME) Interest & Investment Income (2021 - 2026) Analysis & Trends
Zymeworks has reported Interest & Investment Income for 4 years, with the latest figure at -$486000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 189.01% year-over-year to -$486000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$159000.0 (down 112.06% YoY) and the FY2025 annual result came in at $873000.0, up 350.14% from the prior year.
- Interest & Investment Income fell to -$486000.0 in Q1 2026 per ZYME's latest filing, from -$29000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $1.9 million in Q3 2024 and troughed at -$1.9 million in Q2 2023.
- A 4-year average of $7230.8 and a median of -$29000.0 in 2025 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 492.78% in 2024, down 255.69% in 2024.
- Over 4 years, Interest & Investment Income stood at $1.7 million in 2023, then tumbled by 156.22% to -$953000.0 in 2024, then surged by 96.96% to -$29000.0 in 2025, then sank by 1575.86% to -$486000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$486000.0, -$29000.0, and $290000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - | 3.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.29 Mn |
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 3.53 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.42 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Jun 30, 2024 | 5.15 Mn |
| Mar 31, 2024 | 5.92 Mn |
| Dec 31, 2023 | 5.05 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 4.83 Mn |
| Mar 31, 2023 | 4.81 Mn |
| Dec 31, 2022 | 1.73 Mn |
| Sep 30, 2022 | 1.13 Mn |
| Jun 30, 2022 | 436,000.00 |
| Mar 31, 2022 | 302,000.00 |
| Dec 31, 2021 | 296,000.00 |
| Sep 30, 2021 | 340,000.00 |